# Trajectory of cognitive function and quality of life following stenotic aortic valve procedures

**Authors:** Marco Ranucci, Giuseppe Maria Raffa, Luca Ranucci, Luca Brischigiaro, Stefano Casalino, Vittoria Mazzotta, Martina Anguissola, Oronzo Catalano, Matteo Montorfano, Luca Angelo Ferri, Sabrina Ferrante, Maria Teresa La Rovere, Giulio Stefanini, Ottavia Cozzi, Lorenzo Menicanti

PMC · DOI: 10.3389/fcvm.2026.1659733 · Frontiers in Cardiovascular Medicine · 2026-02-06

## TL;DR

This study compares quality of life outcomes after two heart valve procedures and finds similar mental health results but better physical outcomes with surgical replacement at four years.

## Contribution

The study introduces health-related quality of life as a relevant outcome for choosing between surgical and transcatheter aortic valve procedures.

## Key findings

- At 1-year follow-up, both SAVR and TAVI showed similar improvements in mental and physical quality of life.
- At 4-year follow-up, TAVI patients had a significantly higher risk of physical quality of life deterioration compared to SAVR patients.
- Early cognitive impairment was linked to a higher risk of mental quality of life deterioration at 1-year follow-up.

## Abstract

Severe aortic valve stenosis can be treated with either surgical valve replacement (SAVR) or transcatheter valve implantation (TAVI). The choice between these two strategies is guided by the age and clinical profile of the patient. Our study aims to verify the hypothesis that including health-related quality of life (HRQL) as an outcome measure may be relevant to therapeutic choice.

This prospective observational study included 806 patients aged 65–80 years who received either SAVR or TAVI. HRQL was assessed using the SF-12 questionnaire before and after the procedure (1–4 years of follow-up). Propensity score matching was applied to account for baseline differences between groups, resulting in two matched groups of 92 patients each. A subgroup of 80 patients received a neurocognitive function assessment before the procedure and at 2–3 months of follow-up.

At 1-year follow-up, no significant differences were observed between SAVR and TAVI in terms of the mental and physical components of the SF-12, with both procedures resulting in significant improvements in HRQL in both the prematching and propensity-matched populations. In the prematching population, at 4-years follow-up and after adjustment for potential confounders, the cumulative risk of HRQL deterioration did not differ significantly between SAVR and TAVI for the mental component (hazards ratio 1.03, 95% confidence interval 0.69–1.56, P = 0.881), while it was significantly higher (hazards ratio 1.89, 95% confidence interval 1.02–3.59, P = 0.045) for the physical component in the TAVI group. After propensity score matching, these results were confirmed, with no significant differences in the mental component (hazards ratio 1.14, 95% confidence interval 0.65–2.00, P = 0.640) and a significantly higher risk of worsening in the physical component in the TAVI group (hazards ratio 3.91, 95% confidence interval 1.46–10.5, P = 0.007). Early cognitive impairment was associated with a significantly higher risk of deterioration in the mental component at 1-year follow-up (relative risk 3.2, 95% confidence interval 1.18–8.94, P = 0.023).

In a real-world scenario, no differences in quality of life were observed between SAVR and TAVI at 1-year follow-up; conversely, at 4-year follow-up, the physical component of HRQL appeared to be better preserved in patients undergoing SAVR.

## Linked entities

- **Diseases:** aortic valve stenosis (MONDO:0042981)

## Full-text entities

- **Genes:** AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}, ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}
- **Diseases:** hypercholesterolemia (MESH:D006937), heart failure (MESH:D006333), hypertriglyceridemia (MESH:D015228), unstable angina (MESH:D000789), cognitive decline (MESH:D003072), COVID-19 (MESH:D000086382), air micro-embolism (MESH:D004618), cardiovascular disease (MESH:D002318), neurocognitive deterioration (MESH:D019965), AS (MESH:D001024), cerebrovascular accident (MESH:D020521), Cardiomyopathy (MESH:D009202), COPD (MESH:D029424), valvular disease (MESH:D006349)
- **Chemicals:** calcium (MESH:D002118), creatinine (MESH:D003404), P2Y12 antiplatelet agents (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920561/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920561/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920561/full.md

---
Source: https://tomesphere.com/paper/PMC12920561